ABSTRACT
Monocyte chemoattractant protein-1 (MCP-1) is a cytokine which belongs to the CC chemokine family.Retinal pigment epithelium (RPE) cells,photoreceptors and microglial cells in the retina can secrete MCP-1.Physiological level of MCP-1 is important for preserving morphology of RPE and glial cells,as well as retinal function and gross morphology.MCP-1 is likely released from Müller glia and the RPE cells when retina under stress,and attracts microglia/macrophages to the sites of retinal damage,activates the microglia to ingest cell debris.MCP-1 has been found upregulated in the intraocular fluid of retina in patients and animal models with retinal detachment,posterior uveitis and age-related macular degeneration.The expression of MCP-1 may be response to retinal inflammation.Therefore,it is tempting to speculate that pharmacological targeting of MCP-1 may be a safe and viable strategy in treatment of retinal disease.
ABSTRACT
More and more people suffered from the carotid artery obstruction.It is reported that it's around 69% of these patients the first clinical manifestation of carotid occlusive disease is the ocular ischemic syndrome.Owing to the most symptoms of the ocular isehemic syndrome are very obscure,so there are always overlook or made a misdiagnosis of this entity in clinical.Fundus fluorescein angiography (FFA)is the best procedure to find this entity.We should pay close attention to notice the early phase of FFA.It is the most specific FFA sign in ocular ischemic syndrome,and it is a distinctly unusual finding to find the ocular ischemic syndrome.